Site icon pharmaceutical daily

2022 Worldwide Para IV Insights Database – Featuring 3M, Abbott and Abbvie Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Para IV Insights Database – Global Generic Drug Litigation Updates” database has been added to ResearchAndMarkets.com’s offering.

The Para IV database tracks ALL the ongoing Para IV litigations and Patent litigations in the Biologic space (biosimilars) in the US on a real-time basis.

The database has been created over a painstaking 5 years period with a complete history of each Para IV litigation right from the day of the first Para IV filing. The database is not merely a compilation of the legal information, but also includes information from Citizen’s Petition, SEC filings, data from SEC filings and sometimes even call transcripts. In other words, it uses the most comprehensive approach to unravel the strategy behind the Para IV / patent litigation by each involved party.

With this comprehensive approach, the database also offers an educated estimate of the probable timeline of generic entry along with likely competition for each company.

Unique Features:

Unique Search Options:

Other ANDA Filers:

Periodic Reports:

Who can benefit from the Database?:

Generic Pharma Investor

Pharma Investment Banker

Generic Formulation Manufacturer

Generic API Manufacturers

Companies Mentioned

For more information about this database visit https://www.researchandmarkets.com/r/v5bmxx

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version